Coherus Implements Restructuring Plan Following Complete Response Letter For Its Pegfilgrastim Biosimilar

As we reported here on June 12, 2017, Coherus BioSciences received a complete response letter (“CRL”) from the FDA for its biologics license application for its pegfiltrastim (Neulasta®) biosimilar.  On June 21, 2017, in a filing with the SEC, Coherus stated that it is implementing a restructuring plan “to reduce operating costs and better align its workforce with the needs of its business” following receipt of the CRL.  According to the filing, Coherus will reduce its workforce by 51 employees (approximately 30%).